P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO. 2019; 3(1): 22-27 | DOI: 10.14744/ejmo.2018.0020

An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment

Fatma Simsek1, Sevinc Inan2, Mehmet Korkmaz3
1Department of Histology and Embryology, Izmir Katip Celebi University Faculty of Medicine, Izmir, Turkey, 2Department of Histology and Embryology, Izmir University of Economics Faculty of Medicine, Izmir, Turkey, 3Department of Medical Biology, Celal Bayar University Faculty of Medicine, Manisa, Turkey

Objectives: We aimed to investigate the distribution of immunoreactivities of vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inducible NOS (iNOS) on breast cancer cells in response to treatment with boron derivatives. Methods: We initially analyzed the cytotoxic effect and IC50 value of boron by MTT assay. For the evaluation of the angiogenesis, expression level of antibodies was detected to following boron derivatives such as boric acid, boron penta (BP), and T-Boron (DPD) in the absence of boron treatment using the indirect immunohistochemical method. The evaluation of these staining was done using the H-scoring system. Results: It was found that immunoreactivities of VEGF, eNOS, and iNOS increased on control compared to those of the cells of MDA-MB231 human breast cancer cell line. Following boron derivatives treatment, it was observed that they were inhibited the VEGF/NOS labeling in MDA-MB-231 breast cancer cells. Conclusion: The present data suggest that BP, especially DPD, inhibits the angiogenesis of breast cancer cells through VEGF pathway. From this point, these boron derivatives may provide a novel therapeutic approach for breast cancer treatment. Keywords: Boron penta, DPD, Immunohistochemistry, iNOS, MDA-MB-231


Cite This Article

Simsek F, Inan S, Korkmaz M. An in Vitro Study in Which New Boron Derivatives Maybe an Option for Breast Cancer Treatment. EJMO. 2019; 3(1): 22-27

Corresponding Author: Simsek F.

Full Text PDF